849-P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide

耐受性 减肥 胰淀素 体重 医学 内科学 内分泌学 药理学 糖尿病 肥胖 不利影响 小岛
作者
Daniel A. Briere,ANNE LONG,DAWN M. BULLOCK,Libbey S. O’Farrell,BREANNA BOWEN,Katherine Lansu,TAMER COSKUN,Julie S. Moyers,Hongchang Qu
出处
期刊:Diabetes [American Diabetes Association]
卷期号:74 (Supplement_1) 被引量:1
标识
DOI:10.2337/db25-849-p
摘要

Introduction and Objective: Non-selective amylin analogs have shown clinical weight loss benefits, though clinical incidence of nausea and vomiting are high and may require prolonged dosing titrations. Moreover, preclinical studies in rats suggest lean mass preservation versus GLP-1 receptor agonists. Herein, we evaluated weight loss efficacy, GI tolerability, and lean-mass preservation in rats administered eloralintide compared to the non-selective amylin analog, cagrilintide. Methods: Peptides were made using automated peptide synthesizers and evaluated in amylin and calcitonin receptor functional and binding assays. PK and conditioned taste avoidance studies performed using lean rats. Weight loss studies were carried out in lean and DIO rats using QNMR to determine body composition. Results: Eloralintide is an amylin peptide analog modified with a C20 fatty diacid moiety that binds to amylin receptors while retaining selectivity from calcitonin receptors. Eloralintide demonstrated prolonged plasma half-life and reduced clearance compared to cagrilintide. In lean rats, eloralintide matched the food intake reductions of cagrilintide, resulting in a similar degree on body weight change, without the same degree of conditioned taste avoidance. In DIO rats, eloralintide lowered body weight primarily by loss of fat mass and with more potent effects for weight loss efficacy, food intake lowering, and fat mass reductions compared to cagrilintide, with head-to-head studies demonstrating reduced loss of lean mass in comparison to cagrilintide. Conclusion: Eloralintide demonstrated preclinical improvements in efficacy, GI tolerability, and quality of weight loss compared to the non-selective amylin analog cagrilintide. These findings support clinical investigation of eloralintide as a weight loss therapeutic. Disclosure D.A. Briere: Employee; Lilly USA LLC. A. Long: Employee; Eli Lilly and Company. D.M. Bullock: None. L. O'Farrell: None. B. Bowen: Employee; Eli Lilly and Company. K. Lansu: Employee; Eli Lilly and Company. T. Coskun: None. J.S. Moyers: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. H. Qu: Employee; Eli Lilly and Company.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
果称完成签到,获得积分10
刚刚
刚刚
果子发布了新的文献求助10
1秒前
wch666发布了新的文献求助10
1秒前
1秒前
李健的粉丝团团长的应助被Suge采纳,获得10
1秒前
可爱的函函的应助被HJW采纳,获得10
1秒前
1秒前
谢之遥完成签到,获得积分20
1秒前
小蘑菇的应助被lykkk采纳,获得10
2秒前
攸粒子完成签到,获得积分20
2秒前
2秒前
lnx的应助被王哈哈哈哈哈哈哈采纳,获得30
3秒前
清晨的小鹿完成签到,获得积分10
3秒前
丘比特的应助被柠檬采纳,获得10
3秒前
3秒前
4秒前
恢恢发布了新的文献求助10
4秒前
你笑的样子真好看完成签到 ,获得积分10
4秒前
英俊的铭的应助被多情代双采纳,获得10
4秒前
伶俐安萱完成签到,获得积分10
4秒前
4秒前
33Rylee发布了新的文献求助10
5秒前
5秒前
花落云舒发布了新的文献求助10
5秒前
5秒前
宗友绿发布了新的文献求助10
5秒前
在水一方的应助被luca采纳,获得10
5秒前
6秒前
6秒前
聪明的破茧完成签到,获得积分10
6秒前
leungzzz完成签到,获得积分10
6秒前
江城闲鹤完成签到,获得积分10
6秒前
皮蛋发布了新的文献求助10
6秒前
爱科研的chen完成签到,获得积分10
6秒前
Nole的应助被sunny采纳,获得10
7秒前
Clarissa发布了新的文献求助20
7秒前
7秒前
8秒前
老迟到的可兰完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162918
求助须知:如何正确求助?哪些是违规求助? 9557210
关于积分的说明 21738626
捐赠科研通 7753447
什么是DOI,文献DOI怎么找? 3427983
关于科研通互助平台的介绍 2552768
邀请新用户注册赠送积分活动 2472619